Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones - Wikidata - awgldk - TriplyDB

Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones

Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones

http://www.wikidata.org/entity/Q33768910

about

Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors Towards a new combination therapy for tuberculosis with next generation benzothiazinones Decaprenylphosphoryl-β-D-ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis [Better search strategies, hopeful candidates. The search for new antimycobacterial drugs].Drug-resistant tuberculosis: emerging treatment options.Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance Tuberculosis drugs: new candidates and how to find more.Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets.Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1: state of art.Antituberculosis drug research: a critical overview.Resistance in tuberculosis: what do we know and where can we go?The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis.Trends in discovery of new drugs for tuberculosis therapy.Synthetic investigational new drugs for the treatment of tuberculosis.Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.Drug Resistance Mechanisms in Mycobacterium tuberculosis.Azoreductases in drug metabolism.In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis Benzothiazinones mediate killing of Corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall biosynthesis.Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1): challenging target for antitubercular drug discovery.

P2860

Q27672587-C5591174-BF9F-430E-B459-437614CD2F46 Q27681391-3711B344-A67F-455C-A165-B99953A70703 Q27681604-DBAC7591-6683-4C83-9B02-FEFA78159A1A Q28477097-37BBFE8C-9D98-4237-9B70-96C0BEAE6054 Q30318128-2027B54E-56A0-4D62-8E06-B885EBC764FD Q35683967-789955CC-F0C2-4F0F-AA2E-5F259016A778 Q36396241-9759FBFC-2D92-4D4C-8581-E747628566E6 Q37894691-87076F52-A791-40D5-A143-1A7D028FA77F Q37970706-BCDEED16-A736-4A88-A817-4D8A9FBADAC7 Q38004830-BE7135DA-9F09-4B59-B331-D8A9977BEF4C Q38012651-71AE57DD-B53E-47EE-A8C4-8C450A62EAE1 Q38124261-96406FF1-2116-4A01-9E2F-F5E6E5E15F5E Q38137731-F0F9CB29-BE09-4243-A797-97378A08B2A2 Q38237221-066F0658-DF80-4F4A-99FD-8D6DAA32C1B1 Q38635790-60EA037A-6B45-49F0-8B3E-143FBD2A6B03 Q38669601-D56FB57E-B41B-4036-89AD-94E48860F840 Q38751736-7E1FF1EC-13D0-4903-BE76-726E70542BF1 Q38792870-9C787308-39C1-47E0-BD99-9AA25CEE0306 Q38917152-77095B9E-EBE1-4B97-A2E4-D2B93C48267F Q41569899-9C0206EE-2746-4C06-9C9B-72F8E151DE1E Q41984312-F8383510-115E-47A0-8CF0-9DAEDE6569D2 Q55437850-FDE69E31-102C-47A4-AB1D-E57A981474BF

P2860

Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones

http://www.wikidata.org/entity/Q33768910

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Clinical isolates of Mycobacte ...... usceptible to benzothiazinones

@ast

Clinical isolates of Mycobacte ...... usceptible to benzothiazinones

@en

type

label

Clinical isolates of Mycobacte ...... usceptible to benzothiazinones

@ast

Clinical isolates of Mycobacte ...... usceptible to benzothiazinones

@en

prefLabel

Clinical isolates of Mycobacte ...... usceptible to benzothiazinones

@ast

Clinical isolates of Mycobacte ...... usceptible to benzothiazinones

@en

P1433

Q33768910-59F9385A-866F-45E8-BADA-8C3420A791C3

P1476

Q33768910-E097C615-B1C7-49AF-B469-5544BBB07940

P2093

Q33768910-04A71C08-88FE-46AE-8197-CE5F633290D9

Q33768910-0E82EF54-C4E8-4A03-AE42-EC0C7897450B

Q33768910-302D71F1-E8B9-45BB-9FFD-BA0D774D8284

Q33768910-3D1462B9-9947-49F9-BD90-E89EA41D7100

Q33768910-4E1754DF-26E6-41CA-8BBC-F8E9F936F3AE

Q33768910-93106DB5-A56B-4EAC-9BBC-915F72C7A3C7

Q33768910-A46D65D4-C121-4299-9637-9C43D5981287

Q33768910-C41A2576-A72A-4F60-BA99-160B5F94357E

Q33768910-E1E434E0-3CE2-4983-A07D-5399586CC1AA

Q33768910-FD6DC940-CFAC-4F5D-8F50-6AFEB07C3733

P2860

Q33768910-0212A564-7622-44C8-9488-925790357041

Q33768910-108B839B-9577-494A-BA30-2AEB0AEE7CB5

Q33768910-528CC763-2BDE-45CA-ACB9-3127B41F01F6

Q33768910-5C48C206-0144-4435-BDC8-885F5F3D49DA

Q33768910-5C7B90DE-3B54-4D56-9210-BDCACCB7DCD1

Q33768910-ABF02DBA-7F53-4D52-B22C-63866D702BF3

Q33768910-FF327E47-DF67-4E2C-9C1D-F47BF9BD0F65

P304

Q33768910-EAE16B4B-DDA2-4E7E-983A-A3B4C86FAF18

P31

Q33768910-D55327BB-8CD3-48CE-BC3C-4E0F3573B5B2

P356

Q33768910-B9FC9FFF-FF96-45B7-8339-A272485AE420

P407

Q33768910-754A2E7F-8FF5-4DC2-9DC1-54E593A684B2

P433

Q33768910-2189B064-FD87-4412-9F7D-5C264376665D

P478

Q33768910-DE424E5E-58C7-4734-BB73-45CDF42F544A

P50

Q33768910-5CD36795-2418-4D03-BFA0-44D006CFAE5F

Q33768910-651F921C-28F1-4F4C-A6A4-E23D44CBAEE3

Q33768910-8E3192D0-9910-4BC6-AA5A-34A503D5130E

Q33768910-F04A464B-C309-43B8-B768-22EEBD203DBF

P577

Q33768910-A2B2A66B-3798-4FA4-B666-D052B516024D

P5875

Q33768910-CAE34D53-1B4D-4CF8-852A-E11B48199BAA

P698

Q33768910-B0C081D2-EA87-4C20-B9A5-C88F3F4DCC4E

P921

Q33768910-1819042C-33CE-4083-83AA-0878C11ADC2F

P932

Q33768910-10E8FB73-C32F-40F7-B5C6-784FD9DDC4AF

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Clinical isolates of Mycobacte ...... usceptible to benzothiazinones

@en

P2093

Ana Luisa de Jesus Lopes Ribeiro

http://www.w3.org/2001/XMLSchema#string

Beate Heym

http://www.w3.org/2001/XMLSchema#string

Giulia Degiacomi

http://www.w3.org/2001/XMLSchema#string

Leopoldo Pucillo

http://www.w3.org/2001/XMLSchema#string

Maurizio Mirrione

http://www.w3.org/2001/XMLSchema#string

Panajota Troupioti

http://www.w3.org/2001/XMLSchema#string

Patrizia De Mori

http://www.w3.org/2001/XMLSchema#string

Roberto Brerra

http://www.w3.org/2001/XMLSchema#string

Stewart T Cole

http://www.w3.org/2001/XMLSchema#string

Vadim Makarov

http://www.w3.org/2001/XMLSchema#string

P2860

Genes required for mycobacterial growth defined by high density mutagenesis

High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis

Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community.

The biological cost of mutational antibiotic resistance: any practical conclusions?

Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy.

Mycobacterium tuberculosis: drug resistance and future perspectives.

P304

1616-1618

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01676-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Maria Rosalia Pasca

Giovanna Riccardi

P577

2010-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41088252

http://www.w3.org/2001/XMLSchema#string

P698

20086151

http://www.w3.org/2001/XMLSchema#string

P921

Mycobacterium tuberculosis

P932

2849388

http://www.w3.org/2001/XMLSchema#string